Previous 10 | Next 10 |
2024-05-19 06:15:00 ET Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same mol...
2024-05-19 01:04:01 ET Summary Large-cap growth stocks have reasserted themselves in Q2, with the MAGS ETF and Nasdaq 100 reaching all-time highs. I have a buy rating on the Vanguard Russell 1000 Growth Index due to a reasonable valuation given EPS growth trends and its strong mom...
2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...
2024-05-18 11:18:53 ET Summary Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerability and how CT-388 stacks up against key competito...
2024-05-17 20:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-16 13:37:18 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
2024-05-16 09:25:33 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk owner to acquire major stake in Aust...
2024-05-16 07:21:56 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Lilly target price raised at Argus on Mounjaro, Zepbo...
2024-05-16 07:15:00 ET Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others. Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have historically been i...
2024-05-16 06:48:39 ET More on Roche Roche: Value Remains Despite Covid-19 Revenue Growth Loss Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript Q1 2024 Sales/ Trading Statement Call J&J, Roche, AstraZeneca poised to have highest or...
News, Short Squeeze, Breakout and More Instantly...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...